论文部分内容阅读
近年来,乙肝(乙型肝炎)血源疫苗的安全性越来越被人们重视,能否用基因工程疫苗取代血源疫苗,需要有一个完整的、有效的、有说服力的资料。对此,我们应用乙肝基因工程疫苗进行阻断乙肝母婴传播的免疫效果研究,现将结果报告如下。对象与方法1．疫苗及免疫程序:深圳康泰生物制品有限公司研制的维康基因工程乙肝疫苗(酵母重组),批号为2960606—1,失效期98.7.17。疫苗的HBsAg含量均为5μg/0.5ml/支。按0.1.6程序接种,第1针在出生后24小时内完成,总剂量为5μg/次×3。
In recent years, the safety of hepatitis B (HBV) blood-borne vaccines has drawn more and more attention. Whether genetic vaccines can replace blood-borne vaccines requires a complete, valid and persuasive information. In this regard, we apply hepatitis B genetic engineering vaccine for blocking the immune effect of hepatitis B mother to child transmission, the results are reported as follows. Objects and methods 1. Vaccine and immunization program: Weikang genetically engineered hepatitis B vaccine (yeast recombination) developed by Shenzhen Kangtai Biological Products Co., Ltd., lot number 2960606-1, expiration date 98.7.17. Vaccine HBsAg content are 5μg / 0.5ml / support. According to 0.1.6 program inoculation, the first needle is completed within 24 hours after birth, the total dose of 5μg / time × 3.